Full Press Release Details
Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers
BC - January 19, 2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM)
(TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading
the clinical development of cannabinol ("CBN"), today announced that executives of the Company will speak at the 2021
Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe ("CDP Europe"). CDP Europe will be held virtually
from January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry, Manufacturing & Controls, Karen Long - Senior Director,
Drug Development, and Prof. Mauro Maccarrone PhD - Scientific Advisor to InMed will all be featured as expert speakers at the
Michael Woudenberg will participate on a panel discussion on the topic of "Comparing Whole Plant & Synthetic Cannabinoids
& Their Potential in Pharmaceuticals" which will cover topics including the availability of cannabinoids in both
whole plant and synthetic systems, the biggest trade-off between plant-derived and synthetic compounds and comparing cost advantages
in the short and long term.
Karen Long will participate on a panel discussion on the topic of "The Industry Approach to Gaining Drug Approval"
to compare the differences in gaining drug approval around the world including a discussion of case studies.
addition, Prof. Mauro Maccarrone, a member of InMed's Scientific Advisory Board and Professor and Chair of Biochemistry, Department
of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy, will speak on the complexity of the endocannabinoid
system while discussing the critical issues around endocannabinoid signaling regulation in a lecture entitled "Plant-Derived
& Endogenous Cannabinoids: Naturally Different".
are grateful for the opportunity to participate in the CDP Europe event as part of our ongoing commitment to being at the forefront
of novel cannabinoid therapeutics and novel means of manufacturing them," remarked Eric A. Adams, President and Chief Executive
Officer of InMed. "InMed has made important strides in both its therapeutic development and manufacturing programs over
the past year and that has reinforced our position as a leading innovator to speak on these key topics."
more information on the conference, please visit https://cdp-europe.com/.
InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications,
initially focused on the therapeutic benefits of cannabinol ("CBN") in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
For more information, visit www.inmedpharma.com.
Note Regarding Forward-Looking Information:
news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements
about: presenting at the 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe; leading the way in the clinical
development of cannabinol (CBN); developing a pipeline of cannabinoid-based medications in diseases with high unmet medical need;
and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines.
forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation
to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking
information contained herein to reflect future results, events or developments, except as required by law.
THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY
OR ACCURACY OF THIS RELEASE.